254 related articles for article (PubMed ID: 29716549)
21. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
Wu H; Zhang J
Gynecol Oncol; 2018 Jun; 149(3):592-597. PubMed ID: 29602546
[TBL] [Abstract][Full Text] [Related]
22. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
23. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
25. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide characterization of aberrant DNA methylation patterns and the potential clinical implications in patients with endometrial cancer.
Wang Y; Liu D; Jin X; Song H; Lou G
Pathol Res Pract; 2019 Jan; 215(1):137-143. PubMed ID: 30449607
[TBL] [Abstract][Full Text] [Related]
27. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma.
Wang Y; Ren F; Song Z; Wang X; Ma X
J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522
[TBL] [Abstract][Full Text] [Related]
28. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
29. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
[TBL] [Abstract][Full Text] [Related]
30. Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines.
Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; MacLeod RA
Leuk Res; 2010 Apr; 34(4):521-8. PubMed ID: 19608273
[TBL] [Abstract][Full Text] [Related]
31. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
32. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
[TBL] [Abstract][Full Text] [Related]
33. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
Front Oncol; 2021; 11():766947. PubMed ID: 34868993
[TBL] [Abstract][Full Text] [Related]
34. Human
Rathbun LA; Magliocco AM; Bamezai AK
Oncotarget; 2023 May; 14():426-437. PubMed ID: 37141412
[TBL] [Abstract][Full Text] [Related]
35. RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
Lemetre C; Vieites B; Ng CK; Piscuoglio S; Schultheis AM; Marchiò C; Murali R; Lopez-García MA; Palacios JC; Jungbluth AA; Terracciano LM; Reis-Filho JS; Weigelt B
Eur J Cancer; 2016 Sep; 64():149-58. PubMed ID: 27420608
[TBL] [Abstract][Full Text] [Related]
36. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
37. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer.
Li J; Xu W; Zhu Y
Oncol Lett; 2020 Nov; 20(5):255. PubMed ID: 32994818
[TBL] [Abstract][Full Text] [Related]
38. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract][Full Text] [Related]
39. Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer.
Robbins JR; Gayar OH; Zaki M; Mahan M; Buekers T; Elshaikh MA
Gynecol Oncol; 2013 Dec; 131(3):593-7. PubMed ID: 24125752
[TBL] [Abstract][Full Text] [Related]
40. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene.
Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L
Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]